A pooled analysis of two clinical studies (ELEVATE-TN and CL-003), designed to compare PFS and OS for acalabrutinib combined with obinutuzumab versus acalabrutinib monotherapy in patients with TN CLL, clearly showed the benefit of adding obinutuzumab to acalabrutinib monotherapy across genomic subgroups, particularly in those with unmutated IGHV or without del(17p)/TP53 mutations or complex karyotype abnormalities [64]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.